Colon Cleanse Green Tea To Go
Testo originale in francese.
Prodotto naturale per la salute autorizzato in Canada
Se questo prodotto fosse venduto in Francia
- Conditions légales
Contiene tè (Camellia sinensis). Gli estratti di tè verde devono apportare meno di 800 mg di epigallocatechina-3-gallato per porzione giornaliera, con avvertenze obbligatorie.
annexe III, partie B (règlement (UE) 2022/2340). Regolamento (CE) n. 1925/2006, versione consolidata più recente, consultato il 21 ottobre 2026, fonte aggiornata il 26 novembre 2025.
- Conditions légales
Senna alexandrina Mill.: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux enfants de moins de 12 ans, aux femmes enceintes et allaitantes et une mention déconseillant l'usage prolongé.
arrêté du 24 juin 2014, annexe I. Decreti francesi del 9 maggio 2006 (nutrienti), del 24 giugno 2014 (piante) e del 26 settembre 2016 (altre sostanze), raccolta LEGI consolidata, consultato il 23 ottobre 2026.
- Conditions légales
Foeniculum vulgare Mill.: La portion journalière recommandée ne doit pas conduire à une ingestion d'estragole supérieure à 0,05 mg/kg de poids corporel pour les enfants de moins de 12 ans.
arrêté du 24 juin 2014, annexe I. Decreti francesi del 9 maggio 2006 (nutrienti), del 24 giugno 2014 (piante) e del 26 settembre 2016 (altre sostanze), raccolta LEGI consolidata, consultato il 23 ottobre 2026.
- Conditions légales
Camellia sinensis (L.) Kuntze: Seules sont admises la poudre issue du broyage des feuilles et les préparations obtenues à partir des solvants suivants : l'eau, l'alcool à 25 % (v/v), ainsi que les solvants autorisés pour la décaféination ou la suppression des matières irritantes et amères. Les recommandations d'emploi ne doivent pas conduire à une ingestion quotidienne d'EGCG supérieure à 300 mg. L'étiquetage doit comporter des avertissements déconseillant leur prise en dehors des repas, ainsi que leur consommation par les enfants, les adolescents, les femmes enceintes ou allaitantes.
arrêté du 24 juin 2014, annexe I. Decreti francesi del 9 maggio 2006 (nutrienti), del 24 giugno 2014 (piante) e del 26 settembre 2016 (altre sostanze), raccolta LEGI consolidata, consultato il 23 ottobre 2026.
- Conditions légales
Frangula purshiana Cooper: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux enfants de moins de 12 ans, aux femmes enceintes et allaitantes ainsi qu'une mention déconseillant l'usage prolongé.
arrêté du 24 juin 2014, annexe I. Decreti francesi del 9 maggio 2006 (nutrienti), del 24 giugno 2014 (piante) e del 26 settembre 2016 (altre sostanze), raccolta LEGI consolidata, consultato il 23 ottobre 2026.
Si calcola una quantità giornaliera solo per una posologia orale esplicita per adulti, espressa al giorno e in un’unità solida corrispondente alla forma del prodotto. Unità ambigue, liquidi, polveri e dosi pediatriche non vengono estrapolati. Una quantità non calcolata non viene confrontata con i limiti di dose. Questa analisi non costituisce un’autorizzazione alla vendita in Francia né una valutazione di sicurezza o efficacia.
Composizione
| Ingrediente medicinale e fonte | Per unità posologica, secondo la fonte | Massimo giornaliero, adulto |
|---|---|---|
| Senna alexandrina Fonte : Feuille | 555 mg | Non calcolata |
| Foeniculum vulgare subsp. vulgare var. dulce Fonte : Graine(s) | 75 mg | Non calcolata |
| Camellia sinensis Fonte : Feuille | 570 mg | Non calcolata |
| Frangula purshiana Fonte : Écorce âgée | 120 mg | Non calcolata |
| Carthamus tinctorius Fonte : Fleur | 15 mg | Non calcolata |
Ingredienti non medicinali
Vanille (de Tahiti)
Dosi raccomandate in Canada
| Popolazione | Età | Quantità per assunzione | Frequenza |
|---|---|---|---|
| Adultes et adolescents | minimum : 11 ans | 1 tea bag | 1 Tous les jours |
Usi autorizzati in Canada
Stimulant laxative. Used in herbal medicine for the short term relief of occasional constipation. Used in herbal medicine to promote bowel movement by direct action on the large intestine.
Testo originale in inglese.
Un uso autorizzato in Canada non è un’indicazione sulla salute autorizzata nell’Unione europea. Consulti il registro delle indicazioni sulla salute.
Avvertenze in Canada
Known Adverse Reactions : Hypersensitivity is known to occur, in which case discontinue use.
Testo originale in inglese.
Cautions and Warnings : Consult a health care practitioner if symptoms persist. Consult a health care practitioner if symptoms worsen. Consult a health care practitioner prior to use if you are taking thiazide diuretics, corticosteroids, licorice root, or other medications or health products that may aggravate electrolyte imbalance. Consult a health care practitioner prior to use if you have a kidney disorder or are taking cardiac medications such as cardiac glycosides or antiarrhythmic medications. Consult a health care practitioner prior to use if you have fecal impaction or symptoms such as abdominal pain, nausea, vomiting or fever. Reduce dose or discontinue use if you experience abdominal pain, cramps, spasms and/or diarrhoea. Consult a health care practitioner prior to use if you have a liver disorder or develop symptoms of liver trouble (such as abdominal pain, dark urine or jaundice). Consult a health care practitioner prior to use if you have an iron deficiency.
Testo originale in inglese.
Contra-Indications : Do not use if you are pregnant or breastfeeding. Do not use if you have abnormal constrictions of the gastrointestinal tract, potential or existing intestinal blockage, atonic bowel, appendicitis, inflammatory colon disease such as Chron's disease or ulcerative colitis, abdominal pain of unknown origin, undiagnosed rectal bleeding, severe dehydration with depleted water or electrolytes or diarrhoea. Do not use if you are allergic to anethole or plants of the Apiaceae/Carrot family. Do not use if you are taking thiazide diuretics, cardiac glycosides, corticosteroids, stimulant laxatives or other medications which may aggravate electrolyte imbalance. Do not use if you have hypokalemia, high blood pressure, or a kidney or cardiovascular disorder.
Testo originale in inglese.
Scheda del prodotto
- Titolare
- Health Plus Inc.
- NPN o DIN-HM
- 80035455
- Stato
- Licenza attiva
- Data della licenza
- 14 settembre 2012
- Data di revisione
- Non indicata
- Forma
- Sachet de thé
- Via di somministrazione
- Orale
- Tipo di domanda
- Non traditionnelle
Fonte
Scheda ufficiale Health Canada, licenza 80035455
Banca dati dei prodotti naturali per la salute autorizzati (BDPSNH), Health Canada: prodotti autorizzati, ingredienti, dosi, usi e avvertenze, consultato il 27 ottobre 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Testo originale in inglese.
Testo originale in francese.
La formula venduta in Europa con lo stesso nome può essere diversa. Queste informazioni non sostituiscono il parere di un medico o farmacista.
Avvertenze ufficiali (Health Canada)
Health Canada pubblica avvertenze su questi ingredienti:
- Senna alexandrina
Leggere l'avvertenza, quando si applica e gli studi citati
Testo originale ufficiale in inglese.
SENNA - SENNA ALEXANDRINA
Via di somministrazione: Oral
Precauzioni e avvertenze
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a kidney disorder or a lazy bowel (EMA 2018a,b; Brinker 2010; Blumenthal et al. 2000; WHO 1999).
Fonti citate da Health Canada (5)
- Blumenthal M, Goldberg A, Brinkmann J, éditeurs. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2018a: European Medicines Agency. Community Herbal Monograph on Cassia Senna L., fructus and Cassia angustifolia Vahl, fructus. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 25 September 2018. [Accessed 2024 January 10]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-senna-alexandrina-mill-cassia-senna-l-cassia-angustifolia-vahl-fructus-revision-1_en.pdf
- WHO 1999: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 1. Geneva (CH): World Health Organization; 1999.
- OMS 1999 : Organisation mondiale de la Santé (OMS). WHO Monographs on Selected Medicinal Plants, Volume 1. Genève (CH): Organisation mondiale de la Santé; 1999.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking heart medications, corticosteroids, diuretics, or other health products that may contribute to electrolyte imbalance (EMA 2018a,b; Brinker 2010; Blumenthal et al. 2000; WHO 1999).
Fonti citate da Health Canada (5)
- Blumenthal M, Goldberg A, Brinkmann J, éditeurs. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2018a: European Medicines Agency. Community Herbal Monograph on Cassia Senna L., fructus and Cassia angustifolia Vahl, fructus. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 25 September 2018. [Accessed 2024 January 10]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-senna-alexandrina-mill-cassia-senna-l-cassia-angustifolia-vahl-fructus-revision-1_en.pdf
- WHO 1999: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 1. Geneva (CH): World Health Organization; 1999.
- OMS 1999 : Organisation mondiale de la Santé (OMS). WHO Monographs on Selected Medicinal Plants, Volume 1. Genève (CH): Organisation mondiale de la Santé; 1999.
Controindicazioni
Do not use if you are pregnant or breastfeeding (EMA 2018a,b; Brinker 2010; Blumenthal et al. 2000).
Fonti citate da Health Canada (3)
- Blumenthal M, Goldberg A, Brinkmann J, éditeurs. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2018a: European Medicines Agency. Community Herbal Monograph on Cassia Senna L., fructus and Cassia angustifolia Vahl, fructus. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 25 September 2018. [Accessed 2024 January 10]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-senna-alexandrina-mill-cassia-senna-l-cassia-angustifolia-vahl-fructus-revision-1_en.pdf
Do not use if you have inflammatory bowel disease, fever or any undiagnosed gastrointestinal trouble (EMA 2018a,b; Gardner and McGuffin 2013; Brinker 2010; WHO 1999).
Fonti citate da Health Canada (5)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2018a: European Medicines Agency. Community Herbal Monograph on Cassia Senna L., fructus and Cassia angustifolia Vahl, fructus. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 25 September 2018. [Accessed 2024 January 10]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-senna-alexandrina-mill-cassia-senna-l-cassia-angustifolia-vahl-fructus-revision-1_en.pdf
- Gardner Z, McGuffin M. editors. 2013. American Herbal Products Association's Botanical Safety Handbook, 2nd edition. Boca Raton (FL): CRC Press.
- WHO 1999: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 1. Geneva (CH): World Health Organization; 1999.
- OMS 1999 : Organisation mondiale de la Santé (OMS). WHO Monographs on Selected Medicinal Plants, Volume 1. Genève (CH): Organisation mondiale de la Santé; 1999.
Reazioni avverse note
Stop use if hypersensitivity/allergy or diarrhoea occurs (EMA 2018a,b; Blumenthal et al. 2000; WHO 1999).
Fonti citate da Health Canada (4)
- Blumenthal M, Goldberg A, Brinkmann J, éditeurs. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- EMA 2018a: European Medicines Agency. Community Herbal Monograph on Cassia Senna L., fructus and Cassia angustifolia Vahl, fructus. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 25 September 2018. [Accessed 2024 January 10]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-senna-alexandrina-mill-cassia-senna-l-cassia-angustifolia-vahl-fructus-revision-1_en.pdf
- WHO 1999: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 1. Geneva (CH): World Health Organization; 1999.
- OMS 1999 : Organisation mondiale de la Santé (OMS). WHO Monographs on Selected Medicinal Plants, Volume 1. Genève (CH): Organisation mondiale de la Santé; 1999.
- Foeniculum vulgare subsp. vulgare var. dulce
Leggere l'avvertenza, quando si applica e gli studi citati
Testo originale ufficiale in inglese.
BITTER FENNEL- FOENICULUM VULGARE
Via di somministrazione: Oral
Precauzioni e avvertenze
Condizione di applicazione: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024, 2007).
Fonti citate da Health Canada (2)
- EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf
- EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf
Condizione di applicazione: Essential oil and Tincture.
Ask a health care practitioner before use if you are taking any medications including birth control pills or hormone therapy or other health products (EMA 2007).
Fonti citate da Health Canada (1)
- EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf
Reazioni avverse note
Stop use if hypersensitivity/allergy occurs (EMA 2024, 2007).
Fonti citate da Health Canada (2)
- EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf
- EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf
Monografia di Health Canada del 29 novembre 2024
SWEET FENNEL -FOENICULUM VULGARE
Via di somministrazione: Oral
Precauzioni e avvertenze
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024).
Fonti citate da Health Canada (1)
- EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller. subsp. vulgare var. dulce (Mill.) Batt. & Trab., Fructus London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf
Reazioni avverse note
Stop use if hypersensitivity/allergy occurs (EMA 2024).
Fonti citate da Health Canada (1)
- EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller. subsp. vulgare var. dulce (Mill.) Batt. & Trab., Fructus London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf
- Frangula purshiana
Leggere l'avvertenza, quando si applica e gli studi citati
Testo originale ufficiale in inglese.
CASCARA SAGRADA - FRANGULA PURSHIANA
Via di somministrazione: Oral
Precauzioni e avvertenze
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a kidney disorder or a lazy bowel (EMA 2020; Brinker 2010; WHO 2002).
Fonti citate da Health Canada (4)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2020. European Medicines Agency. Community Herbal Monograph on Rhamnus Purshianus D.C., cortex. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 15 January 2020. [Accessed 2024 January 12]. Available from: https://www.fitoterapia.net/archivos/201811/final-community-herbal-monograph-rhamnus-purshianus-dc-cortex_en.pdf?1
- WHO 2002: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 2. Geneva (CHE): World Health Organization; 2002.
- OMS 2002: Organisation mondiale de la Santé. WHO Monographs on Selected Medicinal Plants, Volume 2. Genève (CHE) : Organisation mondiale de la Santé; 2002.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking heart medications, corticosteroids, diuretics, or other health products that may contribute to electrolyte imbalance (EMA 2020; Brinker 2010; WHO 2002; Blumenthal et al. 2000).
Fonti citate da Health Canada (5)
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2020. European Medicines Agency. Community Herbal Monograph on Rhamnus Purshianus D.C., cortex. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 15 January 2020. [Accessed 2024 January 12]. Available from: https://www.fitoterapia.net/archivos/201811/final-community-herbal-monograph-rhamnus-purshianus-dc-cortex_en.pdf?1
- WHO 2002: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 2. Geneva (CHE): World Health Organization; 2002.
- OMS 2002: Organisation mondiale de la Santé. WHO Monographs on Selected Medicinal Plants, Volume 2. Genève (CHE) : Organisation mondiale de la Santé; 2002.
Controindicazioni
Do not use if you are pregnant or breastfeeding (EMA 2020; Brinker 2010; Blumenthal et al. 2000).
Fonti citate da Health Canada (3)
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2020. European Medicines Agency. Community Herbal Monograph on Rhamnus Purshianus D.C., cortex. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 15 January 2020. [Accessed 2024 January 12]. Available from: https://www.fitoterapia.net/archivos/201811/final-community-herbal-monograph-rhamnus-purshianus-dc-cortex_en.pdf?1
Do not use if you have inflammatory bowel disease, fever or any undiagnosed gastrointestinal trouble (EMA 2020; Brinker 2010; WHO 2002).
Fonti citate da Health Canada (4)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2020. European Medicines Agency. Community Herbal Monograph on Rhamnus Purshianus D.C., cortex. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 15 January 2020. [Accessed 2024 January 12]. Available from: https://www.fitoterapia.net/archivos/201811/final-community-herbal-monograph-rhamnus-purshianus-dc-cortex_en.pdf?1
- WHO 2002: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 2. Geneva (CHE): World Health Organization; 2002.
- OMS 2002: Organisation mondiale de la Santé. WHO Monographs on Selected Medicinal Plants, Volume 2. Genève (CHE) : Organisation mondiale de la Santé; 2002.
Reazioni avverse note
Stop use if hypersensitivity/allergy or diarrhea occurs (EMA 2020; Brinker 2010).
Fonti citate da Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2020. European Medicines Agency. Community Herbal Monograph on Rhamnus Purshianus D.C., cortex. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 15 January 2020. [Accessed 2024 January 12]. Available from: https://www.fitoterapia.net/archivos/201811/final-community-herbal-monograph-rhamnus-purshianus-dc-cortex_en.pdf?1
Riguardano l'ingrediente, non questo prodotto né la sua dose. Non sostituiscono il parere medico.
La data della prova di questo elenco di ingredienti è sconosciuta.
Il prodotto è cambiato? Fotografi la confezione.
Un'informazione inesatta o più recente su questo prodotto, che lei sia lettore o marca? Scriva a contact@compoatlas.com: ogni correzione è pubblicata nel registro delle correzioni.